First-in-Human Study of NI006 in Patients With Amyloid Transthyretin Cardiomyopathy
Phase 1
Completed
- Conditions
- Amyloid Transthyretin Cardiomyopathy
- Interventions
- Drug: PlaceboDrug: NI006
- First Posted Date
- 2020-04-24
- Last Posted Date
- 2023-11-03
- Lead Sponsor
- Neurimmune AG
- Target Recruit Count
- 46
- Registration Number
- NCT04360434
- Locations
- 🇪🇸
Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Spain
🇳🇱University Medical Center Groningen, Groningen, Netherlands
🇫🇷Hôpital Henri Mondor, Créteil, France
© Copyright 2025. All Rights Reserved by MedPath